GENE ONLINE|News &
Opinion
Blog

South Korea’s SK Inc., Develops Its CDMO Capabilities via Investment in the Center for Breakthrough Medicines

by Eduardo Longoria
Share To
To come along with the clinical trials conducted by one of SK Inc.’s child companies, SK biopharmaceuticals, SK is taking a wider view of the future and investing in CMO infrastructure with CBM. This is already in the wake of the 2021 creation of SK Pharmateco and acquiring of AMPAC Fine Chemicals, SK biotek, SK biotech Ireland, and Yposkesi. 

It's free! Log in now to read

LATEST
Vaccine Protecting Against 20 Different Pneumococcal Infections Proves Effective in Trial
2022-08-12
FDA Approves Roche’s Established Antiviral For Children Aged Five Or Older
2022-08-12
Novartis Reported Two Deaths Following Zolgensma Gene Therapy
2022-08-12
Extreme Climate Change Is Aggravating Infectious Diseases!
2022-08-11
In Response to Expanding Monkeypox Outbreak, FDA Approves Emergency Use of JYNNEOS Vaccine
2022-08-11
Potential $1 billion Acquisition of TeneoTwo by AstraZeneca comes to Fruition
2022-08-11
Gene Repair Therapy: First Patient Dosed With New Treatment for Sickle Cell Disease
2022-08-11
EVENT
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-20
Cell & Gene Therapy USA 2022
Virtual
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-21
RESI Boston
Boston
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!